Figure 5.

Anti-tumour activity of conatumumab in vivo using PDX xenograft tumours. (A) Two PDX xenograft tumours, EWS1 and EWS4, were surgically implanted subcutaneously in the flanks of NSG mice. Animals were randomised into control and treatment cohorts when the tumour reached around 5 mm in diameter. Once weekly, conatumumab or vehicle injection was performed and the tumour dimensions were measured. Animals were euthanised when the control cohort tumours reached 20 mm in maximal diameter. The tumour growth curves are shown. Comparison of the curves was performed using a two-way ANOVA test, and the P-value is shown. (B) Kaplan–Meier survival analysis of the same mice with EWS1 and EWS4 xenografts at the time the experiment was terminated. (C) EWS1 and EWS4 xenograft tissue lysates were made and subjected to immunoblots for the detection of DR5, and caspase-8 and PARP cleavage. C, control; T1/2, conatumumab-treated tumours.